Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14197243 | 1.00 | LMNA (0.43) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL16207832 | 1.00 | LMNA (0.43) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL2065444 | 1.00 | LMNA (0.43) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL10035082 | 1.00 | LMNA (0.43) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL7920598 | 1.00 | LMNA (0.43) | LMNAALDH1A1KDM4CKDM4APHF8 | |
| SCHEMBL406956 | 0.97 | — | — | |
| SCHEMBL4271641 | 0.89 | — | — | |
| SCHEMBL23879777 | 0.83 | LMNA (0.50) | LMNAALDH1A1BLM | |
| SCHEMBL16764835 | 0.83 | ALDH1A1 (0.39) | LMNAALDH1A1 | |
| SCHEMBL251302 | 0.83 | LMNA (0.34) | LMNAALDH1A1KDM4CKDM4APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007131021-A2 | METHOD OF DETERMINING SUSCEPTIBILITY TO AN ANTIMICROBIAL AGENT | BIONEUTRAL LABORATORIES CORPORATION (US) | 2007-11-15 | — | — | WO | claimed |
| US-20060233886-A1 | Antimicrobial composition and method for making same | FRANCIS, MICHAEL D | 2006-10-19 | — | — | US | claimed |
| US-6117831-A | ALKALI STABILITY; WETTING; USEFUL FOR HARD SURFACE CLEANING, OVEN AND GRILL CLEANING, METAL CLEANING, BOTTLE WASHING, STEAM CLEANING AND WAX STRIPPING | LONZA INC. (US) | 2000-09-12 | — | — | US | claimed |
| EP-3532020-B1 | FEMININE HYGIENE PRODUCTS | RB HEALTH US LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-11576880-B2 | Feminine hygiene products | RB HEALTH (US) LLC (US) | 2023-02-14 | — | — | US | disclosed |
| US-20200367492-A1 | TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT | RECKITT BENCKISER LLC (US) | 2020-11-26 | — | — | US | disclosed |
| EP-3532020-A1 | FEMININE HYGIENE PRODUCTS | RB HEALTH (US) LLC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20190262292-A1 | Feminine Hygiene Products | RB HEALTH (US) LLC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180303090-A1 | TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT | RB HEALTH (US) LLC | 2018-10-25 | — | — | US | disclosed |
| EP-3367792-A1 | TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT | Reckitt Benckiser LLC (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2018078336-A1 | FEMININE HYGIENE PRODUCTS | RECKITT BENCKISER LLC (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2017072482-A1 | TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT | RECKITT BENCKISER LLC (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2007131021-A2 | METHOD OF DETERMINING SUSCEPTIBILITY TO AN ANTIMICROBIAL AGENT | BIONEUTRAL LABORATORIES CORPORATION (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20060233886-A1 | Antimicrobial composition and method for making same | FRANCIS, MICHAEL D | 2006-10-19 | — | — | US | disclosed |
| US-6117831-A | ALKALI STABILITY; WETTING; USEFUL FOR HARD SURFACE CLEANING, OVEN AND GRILL CLEANING, METAL CLEANING, BOTTLE WASHING, STEAM CLEANING AND WAX STRIPPING | LONZA INC. (US) | 2000-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262292-A1 | Feminine Hygiene Products | LDHA, TES, LDHB | LMNA 3927/4885ALDH1A1 217/4885KDM4C 1815/4885 |
| US-11576880-B2 | Feminine hygiene products | LDHA, TES, LDHB | LMNA 3927/4885ALDH1A1 217/4885KDM4C 1815/4885 |
| US-20180303090-A1 | TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT | CUTA, DSG1, SGMS1 | LMNA 3092/4885ALDH1A1 4706/4885KDM4C 4650/4885 |
| US-20200367492-A1 | TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT | CUTA, DSG1, SGMS1 | LMNA 3092/4885ALDH1A1 4706/4885KDM4C 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.